Evotec, Triton Partners
Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal
Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The private equity firm Triton Partners is reportedly considering acquiring Evotec,
News of the offer arrived days after Bloomberg reported that the private equity group Triton Partners, which has built ...
MT Newswires on MSN6h
Halozyme Submits $2.11 Billion Acquisition Offer For EvotecHalozyme Therapeutics (HALO) offered to acquire German drug maker Evotec (EVO) in a deal with an equity value of 2 billion euros ($2.11 billion). Halozyme submitted a non-binding proposal to Evotec's ...
Evotec surged on Friday after Halozyme Therapeutics confirmed it had submitted a non-binding proposal to buy the German ...
Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall around ...
Triton Partners is considering a takeover bid for Germany’s Evotec SE, according to people familiar with the matter, after the private equity firm emerged as one of the drug developer’s ...
Triton Partners, is considering a takeover bid Evotec , Eyk Henning of Bloomberg reported earlier, citing people familiar with the matter. Triton is among several investment firms ...
20h
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to ...
Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...
Halozyme Therapeutics Inc. (HALO) confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback